Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma (Molecular Cancer, (2011), 10, 1, (115), 10.1186/1476-4598-10-115);Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Liu, Qingjun ^a,b   Mier, James W ^a   Panka, David J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Apoptosis Inducing Factor (AIF); Bcl 2; GSK 3 ; HDM2; MI 319; P53; Sorafenib

Indexed keywords

APOPTOSIS INDUCING FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MDM2; PROTEIN P53; SORAFENIB; AIFM1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BENZENESULFONIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INDOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; MI 319; PYRIDINE DERIVATIVE; SPIRO COMPOUND; TP53 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CYTOTOXICITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PROTEIN FUNCTION; PROTEIN TRANSPORT; ANIMAL; CELL NUCLEUS; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE SILENCING; GENETICS; METABOLISM; MITOCHONDRION; MOUSE; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; APOPTOSIS REGULATORY PROTEINS; BENZENESULFONATES; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; MELANOMA; MICE; MICE, NUDE; MITOCHONDRIA; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIDINES; RNA INTERFERENCE; SPIRO COMPOUNDS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052845160     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-021-01378-8     Document Type: Erratum

References (61)

1. Woodgett JR. Judging a protein by more than its name: GSK-3. Sci STKE 2001, 100:re12.
2. Pluquet O, Qu LK, Baltzis D, Koromilas AE. Endoplasmic reticulum stress accelerates p53 degradation by the cooperative actions of Hdm2 and glycogen synthase kinase 3 beta. Mol Cell Biol 2005, 21:9392-405.
3. Qu L, Koromilas AE. Control of tumor suppressor p53 function by endoplasmic stress. Cell Cycle 2004, 3:567-70.
4. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Progress in Neurobiol 2006, 79:173-98.
5. Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3β suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2003, 2:1215-22.
6. King TD, Jope RS. Inhibition of GSK3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport 2005, 16:597-601.
7. Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J, Fine HA. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-myc, nuclear factor-κB, and glucose regulation. Cancer Res 2008, 68:6643-51.
8. Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci USA 2008, 105:7785-90.
9. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O, Selivanova G. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009, 15:441-53.
10. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006, 21:749-60.
11. Hammond EM, Giaccia AJ. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 2005, 331:718-25.
12. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001, 268:2764-72.
13. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998, 12:2973-83.
14. Hammond EM, Dorie MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 2003, 278:12207-13.
15. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-34.
16. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
17. Baltzis D, Pluquet O, Papadakis AI, Kazemi S, Qu LK, Koromilas AE. The eIF2 alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. J Biol Chem 2007, 282:31675-87.
18. Ghosh JC, Altieri DC. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3 beta in colorectal cancer cells. Clin Cancer Res 2005, 11:4580-8.
19. Kulikov R, Boehme KA, Blattner C. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol 2005, 16:7170-80.
20. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nature Cancer Rev 2009, 9:724-37.
21. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
22. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-14.
23. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-30.
24. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004, 5:443-50.
25. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003, 3:577-90.
26. Talos F, Petrenko O, Mena P, Moll UM. Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res 2005, 65:9971-81.
27. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta 2009, 1787:414-20.
28. Wolff S, Erster S, Palacios G, Moll UM. p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res 2008, 18:733-44.
29. Baritaud M, Boujrad H, Lorenzo HK, Krantic S, Susin SA. Histone H2AX: The missing link in AIF-mediated caspase-independent programmed necrosis. Cell Cycle 2010, 9:3166-73.
30. Erster S, Moll UM. Stress-induced p53 runs a transcription-independent death program. Biochem Biophys Res Commun 2005, 331:843-50.
31. Norberg E, Orrenius S, Zhivotovsky B. Mitochondrial regulation of cell death: Processing of apoptosis-inducing factor (AIF). Biochem Biophys Res Comm 2010, 396:95-100.
32. Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003, 2:102-9.
33. LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1 alpha and Hdm2. Cancer Res 2007, 67:450-4.
34. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008, 14:5318-24.
35. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009, 49:223-41.
36. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-8.
37. Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009, 15:171-83.
38. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM2 interaction and activates p53 function in tumors. Nat Med 2004, 10:1321-7.
39. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS. Glycogen synthase kinase-3 beta (GSK3 beta) binds to and promotes the actions of p53. J Biol Chem 2003, 278:48872-9.
40. Panka DJ, Cho DC, Atkins MB, Mier JW. GSK-3β inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem 2008, 283:726-32.
41. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nature Chem Biol 2006, 2:4749.
42. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatinum and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27:2823-30.
43. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008, 26:2178-85.
44. Bastin-Coyette L, Cardoen S, Smal C, de Viron E, Arts A, Amsailale R, Van Den Neste E, Bontemps F. Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines. Biochem Pharmacol 2011, 81:586-93.
45. Starostina NG, Simpliciano JM, McGuirk MA, Kipreos ET. CRL2 (LRR-1) targets a CDK inhibitor for cell cycle control in C. elegans and actin-based motility regulation in human cells. Dev Cell 2010, 19:753-64.
46. Panka DJ, Wang W, Atkins MB, Mier JW. The raf inhibitor BAY 43-9006 (sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006, 66:1611-9.
47. Norberg E, Gogvadze V, Vakifahmetoglu H, Orrenius S, Zhivotovsky B. Oxidative modification sensitizes mitochondrial apoptosis-inducing factor to calpain-mediated processing. Free Rad Biol Med 2010, 48:791-7.
48. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, Zhang D. Direct interaction between Nrf2 and p21 (Cip/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 2009, 34:663-73.
49. Ciani L, Salinas PC. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci 2005, 6:531-62.
50. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-myc as a target of the APC pathway. Science 1998, 281:1509-12.
51. Nakayama KI, Nakayama K. Ubiquitin ligases: cell cycle control and cancer. Nat Rev Cancer 2006, 6:369-381.
52. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of beta-catenin by activated p53. Mol Cell Biol 2001, 21:6768-80.
53. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumor suppressor at the crossroads of cell division and differentiation. Nature Rev Cancer 2008, 8:83-97.
54. Panka DJ, Sullivan RJ, Mier JW. An inexpensive, specific and highly sensitive protocol to detect the BRAFV600E mutation in melanoma tumor biopsies and blood. Melanoma Res 2010, 20:401-7.
55. Lomax MI, Hewett-Emmett D, Yang TL, Grossman LI. Rapid evolution of the human gene for cytochrome c oxidase subunit IV. Proc Natl Acad Sci USA 1992, 89:5266-5270.
56. Nevins JR. Isolation and analysis of nuclear RNA. Meth Enzymol 1987, 152:234-236. Academic Press.
57. Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, Atkins MB, Regan M, Signoretti S, Lenkinski RE, Goldberg SN. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?. Radiology 2009, 251:731-742.
58. Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, Signoretti S, Raptopoulos VD, Goldberg SN. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 2008, 191:133-9.
59. Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer 2009, 8:115-128.
60. Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 2010, 46:1122-31.
61. Takeshita M, Tani T, Harada S, Hayashi H, Itoh H, Tajima H, Ohnishi I, Takamura H, Fushida S, Kayahara M. Role of transcription factors in small intestinal ischemia-reperfusion injury and tolerance induced by ischemic preconditioning. Transplant Proc 2010, 42:3406-13.